Growth Hormone, Growth Factor Other Than T-cell Or B-cell Growth Factor, And Growth Hormone Releasing Factor; Related Peptides Patents (Class 930/120)
  • Patent number: 9034826
    Abstract: The present invention is relevant to human medicine, and, in particular, to the use of Epidermal Growth Factor (EGF) in a pharmaceutical composition, said composition is administered through infiltration at the periphery of nerve trunks and/or ganglia, for the morphofunctional restoration of peripheral nerves in painful, sensory-motor neuropathy, as well as ischemic neuritis. It is also relevant to an EGF containing composition, where this molecule can be formulated together with anesthetic or analgesic drugs, or encapsulated in microspheres, and their use for the morphofunctional restoration of peripheral nerves in painful, sensory-motor neuropathy, as well as in ischemic neuritis.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: May 19, 2015
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Jose Ignacio Fernandez Montequin, Luis Saturnino Herrera Martinez, Jorge Amador Berlanga Acosta, Diana Garcia Del Barco Herrera, Danay Cibrian Vera, Gerardo Enrique Guillen Nieto, Raimundo Ubieta Gomez, Sonia Gonzalez Blanco, Vivian Maria Saez Martinez
  • Patent number: 8937043
    Abstract: The invention concerns a method for obtaining a highly enriched TGF-beta protein fraction in activated form, from a liquid solution rich in proteins said to be soluble in the aqueous phase of milk and/or of whey, said method comprising the following steps; a) adjusting soluble proteins purified at a concentration between 5 and 30 g/liter of solution; b) precipitating part of the whey proteins by acidic treatment of the solution thus obtained to a pH ranging between 4 and 5.5 and at a temperature ranging between 55° C. and 68° C.; c) carrying out a microfiltration of the treated solution by diafiltration, so as to obtain respectively a microfiltration retentate and a microfiltrate; d) recuperating the microfiltration retentate containing the protein fraction highly enriched in TGF-beta; e) drying the microfiltration retentate which has been subjected to diafiltration to obtain a powder highly enriched in TGF-beta.
    Type: Grant
    Filed: July 13, 2005
    Date of Patent: January 20, 2015
    Assignee: Piere Jouan Biotechnologies S.A.
    Inventors: Jean-Louis Maubois, Jacques Fauquant, Pierre Jouan, Michel Bourtourault
  • Patent number: 8722626
    Abstract: The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms of cutaneous fibrosis of any etiopathogenesis. Additionally, these peptides prevent and eradicate deposition of amiloid and hyaline materials in any of their correspondent chemical forms and tissue manifestations in the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin, among others. By this way, cellular, tissular and organ dysfunctions generated by these depositions are corrected. The peptides of the present invention are infiltrated or topically applied, contributing to prevent and eradicate keloids and hypertrophic scars in the skin, derived as sequelae of burns and other cutaneous trauma.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: May 13, 2014
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Jorge Berlanga Acosta, Danay Cibrian Vera, Diana Garcia Del Barco Herrera, Gerardo Enrique Guillén Nieto, José Suarez Alba, Ernesto Lopez Mola, Manuel Selman-Housein Sosa, Mariela Vazquez Castillo
  • Patent number: 8642552
    Abstract: The invention relates to human medicine and to the use of epidermal growth factor (EGF) for preparing a pharmaceutical composition which is administered by infiltration into the periphery of nerve ganglia and/or trunks for the morphofunctional restoration of peripheral nerves in painful sensory-motor neuropathy as well as manifestations of ischemic neuritis. The invention also includes a composition containing EGF which can be formulated together with anesthetics or analgesics or encapsulated in microspheres and to the use thereof for the morphofunctional restoration of peripheral nerves in painful sensitive-motor-type diabetic neuropathy and the manifestations of ischemic neuritis.
    Type: Grant
    Filed: October 1, 2007
    Date of Patent: February 4, 2014
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Jose Ignacio Fernandez Montequin, Luis Saturnino Herrera Martinez, Jorge Amador Berlanga Acosta, Diana Garcia Del Barco Herrera, Danay Cibrian Vera, Gerardo Enrique Guillen Nieto, Raimundo Ubieta Gomez, Sonia Gonzalez Blanco, Vivian Maria Saez Martinez
  • Patent number: 8530191
    Abstract: A method for reducing or substantially preventing formation of a trisulfide derivative of a polypeptide in a liquid medium containing the polypeptide ijn question comprises stripping the liquid medium with a gas, suitably a chemically unreactive gas such as nitrogen or argon.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: September 10, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Peter Becker, Thorkild Christensen
  • Patent number: 8507433
    Abstract: Whether the growth hormone (GH)/Insulin-like growth factor 1(IGF-I) axis exerts cardioprotective effects remains controversial; and the underlying mechanism(s) for such actions are unclear. Here we tested the hypothesis that growth-hormone releasing hormone (GHRH) directly activates cellular reparative mechanisms within the injured heart, in a GH/IGF-I independent fashion. Following experimental myocardial infarction (MI), rats were randomly assigned to receive, during a 4 week period, either placebo (n=14), rat recombinant GH (rrGH, n=8) or JI-38 (n=8; 50 ?g/Kg/day), a potent GHRH-agonist. JI-38 did not elevate serum levels of GH or IGF-I, but markedly attenuated the degree of cardiac functional decline and remodeling after injury. In contrast, GH administration markedly elevated body weight, heart weight, circulating GH and IGF-I, but did not offset the decline in cardiac structure and function.
    Type: Grant
    Filed: October 28, 2010
    Date of Patent: August 13, 2013
    Assignees: University of Miami, The United States of America, represented by the Deptartment of Veterans Affairs
    Inventors: Andrew V. Schally, Norman L Block, Joshua Hare, Rosemeire Miyuki Kanashiro Takeuchi
  • Patent number: 8461110
    Abstract: Peptides having a structure characterized by the presence of two loops constrained in cyclic structure by the presence of covalent bonds between amino acid side chains, the amino acid sequences of the first and the second loop being substantially homologues to that of loop 1 (residues 29-38) and of loop 4 (residues 92-97) of NGF, respectively, displaying nerve growth factor (NGF) agonist or partial agonist activity.
    Type: Grant
    Filed: June 9, 2006
    Date of Patent: June 11, 2013
    Assignee: Blueprint Pharma S.R.L.
    Inventors: Luigi Vitagliano, Laura Zaccaro, Giancarlo Morelli, Enzo Martegani
  • Patent number: 8324151
    Abstract: Methods are disclosed for treating sepsis and septic shock using a combination of ghrelin and growth hormone, and for using ghrelin to reduce organ and tissue injury and improve survival after combined radiation exposure and sepsis.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: December 4, 2012
    Assignee: The Feinstein Institute for Medical Research
    Inventor: Ping Wang
  • Patent number: 8105603
    Abstract: The present invention relates to polypeptides that inhibit APRIL and/or BAFF binding to BCMA, nucleic acid molecules encoding the polypeptides, and compositions comprising the polypeptides. The present invention also relates to methods for treating an immune-related disease or cancer using the polypeptides and compositions of the invention. The present invention also relates to methods for identifying inhibitors of APRIL/BAFF binding to BCMA and APRIL/BAFF signaling.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: January 31, 2012
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Darshana Ramesh Patel
  • Patent number: 7960123
    Abstract: The present invention relates to a method and means for diagnosing or risk stratification of co-morbidities, particularly cardiovascular complications in diabetes patients. The invention particularly relates to a method for diagnosing whether a diabetes patient is suffering from a cardiovascular complication or is at risk of suffering from a cardiovascular complication, said method comprising the steps of (a) measuring, preferably in vitro, the level(s) of at least one cardiac hormone or a variant thereof in a sample from the patient, and (b) diagnosing the cardiovascular complication or the risk of suffering from cardiovascular complication by comparing the measured level(s) to known level(s) associated with the cardiovascular complication or risk. The present invention also relates to combining the measurement of markers comprising cardiac hormones, natriuretic peptides, inflammation-associated markers, angiogenesis-markers, and markers for platelet activation.
    Type: Grant
    Filed: July 6, 2005
    Date of Patent: June 14, 2011
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Georg Hess, Andrea Horsch
  • Patent number: 7785588
    Abstract: NTNR?, NTNR? extracellular domain (ECD), NTNR? variants, chimeric NTNR? (e.g., NTNR? immunoadhesion), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNR?-ligands, for example NTN, by providing NTNR? to the cell.
    Type: Grant
    Filed: August 22, 2006
    Date of Patent: August 31, 2010
    Assignee: Genentech, Inc.
    Inventors: Robert D. Klein, Arnon Rosenthal, Mary A. Hynes
  • Patent number: 7553930
    Abstract: The invention relates to novel proteins with BAFF dominant negative antagonist, receptor antagonist activity and agonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of BAFF or APRIL-related disorders.
    Type: Grant
    Filed: March 5, 2004
    Date of Patent: June 30, 2009
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Adam Read Thomason, Eugene Alexander Zhukovsky
  • Patent number: 7300772
    Abstract: Purified BMP-2 and BMP-4 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: November 27, 2007
    Assignee: Genetics Institute, LLC
    Inventors: Elizabeth A. Wang, John M. Wozney, Vicki A. Rosen
  • Patent number: 7220558
    Abstract: Nucleotide and amino acid sequences of cartilage-derived morphogenetic proteins (CDMP-1 and CDMP-2) from human and bovine cartilage extracts. These proteins exhibit chondrogenic activity and can be used to repair cartilage defects in a mammal.
    Type: Grant
    Filed: March 3, 2003
    Date of Patent: May 22, 2007
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Frank P. Luyten, Malcolm Moos, Jr., Steven Chao-Huan Chang
  • Patent number: 7176292
    Abstract: The present invention concerns a protein produced from an alternative splice form of the human Ghrelin gene, an obesity and/or diabetes related gene.
    Type: Grant
    Filed: September 11, 2003
    Date of Patent: February 13, 2007
    Assignee: Dialean, Ltd.
    Inventor: Liat Mintz
  • Patent number: 7141262
    Abstract: The invention concerns a method for obtaining a highly enriched TGF-beta protein fraction in activated form, from a liquid solution rich in proteins said to be soluble in the aqueous phase of milk and/or of whey, said method comprising the following steps; a) adjusting soluble proteins purified at a concentration between 5 and 30 g/liter of solution; b) precipitating part of the whey proteins by acidic treatment of the solution thus obtained to a pH ranging between 4 and 5.5 and at a temperature ranging between 55° C. and 68° C.; c) carrying out a microfiltration of the treated solution by diafiltration, so as to obtain respectively a microfiltration retentate and a microfiltrate; d) recuperating the microfiltration retentate containing the protein fraction highly enriched in TGF-beta; e) drying the microfiltration retentate which has been subjected to diafiltration to obtain a powder highly enriched in TGF-beta.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: November 28, 2006
    Assignee: Pierre Jouan Biotechnologies S.A.
    Inventors: Jean-Louis Maubois, Jacques Fauguant, Pierre Jouan, Michel Bourtourault
  • Patent number: 7090834
    Abstract: The present invention provides VEGF variants having one or more amino acid mutations in the KDR and/or FLT-1 receptor binding domains in the native VEGF sequence and selective binding affinity for either the KDR receptor or the FLT-1 receptor. Methods of making the VEGF variants and methods of using the VEGF variants are also provided.
    Type: Grant
    Filed: April 10, 2000
    Date of Patent: August 15, 2006
    Assignee: Genentech, Inc.
    Inventors: Brian C. Cunningham, Abraham M. de Vos, Bing Li
  • Patent number: 6966992
    Abstract: The current invention provides methods for molecule purification by RP-LC and RP-HPLC that uses unbranched terminal alkyldiols as eluting solvents. In particular, the present invention purifies molecules, particularly proteins and peptides, on reverse phase liquid chromatography columns using a buffer containing either 1,5 pentanediol, 1,6 hexanediol or 1,7 heptanediol.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: November 22, 2005
    Assignee: Akzo Nobel NV
    Inventors: Terry Allen Hauser, Kirk James Hayenga
  • Patent number: 6849597
    Abstract: An agent for prevention or treatment of diseases involving degeneration or death of nerve cells, characterized by containing a growth hormone secretion promoting substance as an active ingredient, is provided.
    Type: Grant
    Filed: December 28, 2000
    Date of Patent: February 1, 2005
    Assignee: Kaken Pharmaceutical Co., Ltd.
    Inventors: Takahiko Murata, Tadashi Ohyama, Masahiro Amakawa, Keiko Fujita, Haruyoshi Ueo
  • Patent number: 6787336
    Abstract: The present invention relates to DNA molecules which encode antagonists of vertebrate growth hormones obtained by mutation of at least the amino acid corresponding to Glu-119 in bovine growth hormone. The DNA molecules may be used to express the antagonists, either in cell culture, or in the cells of the patient of interest. The antagonist so expressed may be used to inhibit GH activity in a subject.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 7, 2004
    Assignee: Ohio University/Edison Biotechnology Institute
    Inventors: John J. Kopchick, Wen Y. Chen
  • Patent number: 6764683
    Abstract: There is disclosed a novel genus of small peptides, much smaller than human TGF&agr;, was discovered as having TGF&agr; biological activity and therefore are useful as pharmacologic agents for the same indications as full length TGF&agr; polypeptide. There is further disclosed that TGF&agr; and consequently the genus of small peptides disclosed herein, was found to have therapeutic activity to stimulate hematopoiesis in patients undergoing cytotoxic cancer chemotherapy and to act as a cytoprotective agent to protect a patient undergoing cancer cytotoxic therapy from gastrointestinal (GI) side effects, such as mucositis and otherwise support the barrier function of the GI tract when it is harmed by cytotoxic therapy.
    Type: Grant
    Filed: December 13, 1999
    Date of Patent: July 20, 2004
    Assignee: Kaleidos Pharma, Inc.
    Inventors: Daniel R. Twardzik, Stefan Paskell, Thomas S. Felker
  • Patent number: 6756357
    Abstract: The variants of human ciliary neutrophic factor (hCNTF) according to the present invention are characterized by substitution of phenylalanine 152 and/or lysine 155 with alanine. These variants have biological properties that render them important as the active principles of drugs for the treatment of diseases and pathologies involving the nervous system or other pathologies involving cells responding to the CNTF. FIG. 2 shows the results of simulation of haptoglobin secretion from HepG2 cells by CNTF and the variants described in the invention.
    Type: Grant
    Filed: July 6, 1999
    Date of Patent: June 29, 2004
    Assignee: Istituto di Richerche di Biologia Molecolare di Angeletti S.p.A.
    Inventors: Ralph Laufer, Annalise Di Marco
  • Patent number: 6713451
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: March 30, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Patent number: 6696414
    Abstract: The invention relates to treatment of patients in need of increasing insulin sensitivity by administration of growth hormone or analogues thereof, preferably human growth hormone, in a low dose and the use of growth hormone or analogues thereof, preferably human growth hormone, for the manufacturing of a medicament useful for increasing insulin sensitivity in low dose therapy. The patient is preferably a normal subject, i.e. not growth hormone deficient patient and/or a non-obese patients. By low dose therapy is preferably meant less than 0.008 mg/kg/day, preferably 0.007 mg/kg/day or less, more preferably 0.005 mg/kg/day or less and most preferably 0.003 mg/kg/day or less. The therapy is preferably performed during short term treatment, preferably less than one month.
    Type: Grant
    Filed: March 13, 2001
    Date of Patent: February 24, 2004
    Assignee: Pharmacia AB
    Inventor: David B. Dunger
  • Patent number: 6693079
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: February 17, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Patent number: 6693078
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: February 17, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Patent number: 6683053
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 27, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Patent number: 6680298
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 20, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Patent number: 6632794
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: October 14, 2003
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Patent number: 6620789
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: September 16, 2003
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C.A.F. Robinson
  • Patent number: 6608028
    Abstract: Peptides are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist peptides are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: August 19, 2003
    Assignee: Genentech, Inc.
    Inventors: Yvonne Man-yee Chen, Ross G. Clark, Andrea G. Cochran, Henry B. Lowman, Iain C. A. F. Robinson, Nicholas J. Skelton
  • Patent number: 6559289
    Abstract: The invention relates to the use of compounds selected from GH, analogues thereof, and GH-releasing compounds, optionally in combination with lipid-lowering agents or therapy, for the preparation of a drug for treatment of mammals with familial hypercholesterolemia of homozygous form.
    Type: Grant
    Filed: April 23, 2001
    Date of Patent: May 6, 2003
    Assignee: Salhtech I Goteborg AB
    Inventors: Mats Rudling, Bo Angelin
  • Patent number: 6458764
    Abstract: The present invention relates to chimeric fatty body-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.
    Type: Grant
    Filed: September 3, 1999
    Date of Patent: October 1, 2002
    Assignee: Theratechnologies Inc.
    Inventors: Denis Gravel, Abdelkrim Habi, Paul Brazeau
  • Patent number: 6426329
    Abstract: The invention provides a composition for improving an action of an immunosuppressant, comprising insulin-like growth factor I or its analog as an active ingredient.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: July 30, 2002
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Ikuo Kawamura, Mariko Ohta, Shigeru Takeshita
  • Patent number: 6287816
    Abstract: Purified bone morphogenetic protein-9 (BMP-9) proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.
    Type: Grant
    Filed: June 6, 1994
    Date of Patent: September 11, 2001
    Assignee: Genetics Institute, Inc.
    Inventors: Vicki A. Rosen, John M. Wozney, Anthony J. Celeste, R. Scott Thies, Jeffrey R. Song
  • Patent number: 6271346
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 7, 2001
    Assignee: Amgen Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • Patent number: 6238915
    Abstract: In accordance with the present invention, there are provided mutant human growth hormone proteins which exhibit enhanced affinity for growth hormone but lowered hormone activity, base sequences encoding the same and their production processes as well as uses of said proteins. The proteins according to the present invention, with their enhanced affinities for the growth hormone receptor, can inhibit the binding of growth hormone to its receptor, while they retain lowered growth hormone activities, thus finding application as a medicament for the treatment of acromegaly and gigantism.
    Type: Grant
    Filed: February 12, 1997
    Date of Patent: May 29, 2001
    Assignee: JCR Pharmaceuticals Co., Ltd.
    Inventor: Kazuo Chihara
  • Patent number: 6222022
    Abstract: A novel growth factor, persephin, which belongs to the GDNF/neurturin family of growth factors, is disclosed. The human, mouse and rat amino acid sequences have been identified. Human, mouse and rat persephin genomic DNA sequences have been cloned and sequenced and the respective cDNA sequences identified. In addition, methods for treating degenerative conditions using persephin, methods for detecting persephin gene alterations and methods for detecting and monitoring patient levels of persephin are provided. Methods for identifying additional members of the persephin-neurturin-GDNF family of growth factors are also provided.
    Type: Grant
    Filed: September 16, 1997
    Date of Patent: April 24, 2001
    Assignee: Washington University
    Inventors: Eugene M. Johnson, Jeffrey D. Milbrandt, Paul T. Kotzbauer, Patricia A. Lampe, Robert Klein, Fred DeSauvage
  • Patent number: 6174857
    Abstract: Pharmaceutical compositions and methods for the treatment of osteoporosis in mammals are disclosed. The compositions are suitable for parenteral administration and comprise Insulin-Like Growth Factor I (IGF-I) and a pharmaceutically acceptable carrier. The compositions for use in the methods may also include bone antiresorptive compounds.
    Type: Grant
    Filed: December 30, 1996
    Date of Patent: January 16, 2001
    Assignee: Novartis Corporation
    Inventor: Robert Roland B{umlaut over (u)}rk
  • Patent number: 6159934
    Abstract: Described are novel uses of GHRH-RP polypeptides for specifically activating Sertoli cell expression of stem cell factor and promoting spermatogenesis and fertility, and for inhibiting GHRH-RP activity to decrease or eliminate spermatogenesis and fertility. Also described are pharmaceutical compositions for such uses, and transgenic animals lacking expression of or expressing introduced DNA encoding GHRH-RP polypeptides.
    Type: Grant
    Filed: December 20, 1996
    Date of Patent: December 12, 2000
    Assignee: Indiana University Foundation
    Inventor: Ora H. Pescovitz
  • Patent number: 6153581
    Abstract: Drug which contains human growth hormones capable of recovering the renal function when administered to a patient who has renal insufficiency but has not yet undergone kidney dialysis. By administrating the drug, the loss of renal function represented by an extreme decrease in creatinine clearance or the reciprocal of blood creatinine level can be prevented and thus it can dispense with the dialytic treatment for patients with renal insufficiency.
    Type: Grant
    Filed: March 27, 1998
    Date of Patent: November 28, 2000
    Assignee: Sumitomo Pharmaceuticals Company
    Inventor: Tsutomu Sanaka
  • Patent number: 6143523
    Abstract: Human growth hormone variants and their nucleic acids are disclosed wherein the amino acid residues at positions 10, 14, 18, 21, 167, 171, 174, 176 and 179 have been replaced with other amino acids. Also claimed are vectors and host cells comprising these human growth hormone variants as well as processes for their preparation.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 7, 2000
    Assignee: Genentech, Inc.
    Inventors: Brian C. Cunningham, Henry Lowman, James A. Wells
  • Patent number: 6136563
    Abstract: Human growth hormone variants are disclosed having enhanced affinity for the growth hormone receptor. Also disclosed are human growth hormone variants conjugated to one or more chemical groups, such as poly(ethylene glycol), which is believed to prolong the in vivo half-life of the variants.
    Type: Grant
    Filed: February 24, 1998
    Date of Patent: October 24, 2000
    Assignee: Genentech, Inc.
    Inventors: Brian C. Cunningham, James A. Wells, Ross G. Clark, Kenneth Olson, Germaine G. Fuh
  • Patent number: 6057292
    Abstract: Human growth hormone variants are disclosed having enhanced affinity for the growth hormone receptor. Also disclosed are human growth hormone variants conjugated to one or more chemical groups, such as poly(ethylene glycol), which is believed to prolong the in vivo half-life of the variants.
    Type: Grant
    Filed: February 24, 1998
    Date of Patent: May 2, 2000
    Assignee: Genentech, Inc.
    Inventors: Brian C. Cunningham, Henry B. Lowman, James A. Wells, Ross G. Clark, Kenneth Olson, Germaine G. Fuh
  • Patent number: 6034061
    Abstract: Purified Bone Morphogenetic Protein (BMP)-9 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair, and in hepatic growth and function.
    Type: Grant
    Filed: December 4, 1996
    Date of Patent: March 7, 2000
    Assignee: Genetics Institute, Inc.
    Inventors: Vicki A. Rosen, John M. Wozney, Anthony J. Celeste, Scott R. Thies, Jeffrey R. Song
  • Patent number: 6034062
    Abstract: Purified Bone Morphogenetic Protein (BMP)-9 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair, and in hepatic growth and function.
    Type: Grant
    Filed: March 13, 1997
    Date of Patent: March 7, 2000
    Assignee: Genetics Institute, Inc.
    Inventors: R. Scott Thies, Jeffrey J. Song
  • Patent number: 6001968
    Abstract: The present invention relates generally to the control of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of body weight, and to diagnostic and therapeutic uses of such modulators. In its broadest aspect, the present invention relates to nucleotide sequences corresponding to the murine and human OB gene, and two isoforms thereof, and proteins expressed by such nucleotides or degenerate variations thereof, that demonstrate the ability co participate in the control of mammalian body weight and that have been postulated to play a critical role in the regulation of body weight and adiposity. The present invention further provides nucleic acid molecules for use as molecular probes or as primers for polymerase chain reaction (PCR) amplification. In further aspects, the present invention provides cloning vectors and mammalian expression vectors comprising the nucleic acid molecules of the invention.
    Type: Grant
    Filed: August 17, 1994
    Date of Patent: December 14, 1999
    Assignee: The Rockefeller University
    Inventors: Jeffrey M. Friedman, Yiying Zhang, Ricardo Proenca
  • Patent number: 5977068
    Abstract: The present invention relates to compositions of growth hormones and preservatives which do not interfere with the activity of the growth hormone.
    Type: Grant
    Filed: December 16, 1991
    Date of Patent: November 2, 1999
    Assignee: American Cyanamid Company
    Inventors: Praveen Tyle, Brenda Lee Balint Probasco, Susan Mancini Cady
  • Patent number: 5958879
    Abstract: The present invention relates to antagonists of vertebrate growth hormones obtained by mutation of the third alpha helix of such proteins (especially bovine or human GHs). These mutants have growth-inhibitory or other GH-antagonizing effects. These novel hormones may be administered exogenously to mammals. The antagonists may be used to reduce the activity of growth hormone in a mammal, especially one suffering from diabetes, diabetic retinopathy, diabetic nephropathy, a growth hormone secreting tumor, acromegaly, or gigantism.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 28, 1999
    Assignee: Ohio University/Edison Biotechnology Institute
    Inventors: John J. Kopchick, Wen Y. Chen
  • Patent number: RE37850
    Abstract: Endothelial cell growth factor is achieved through the application of recombinant DNA technology to prepare cloning vehicles encoding the ECGF protein and procedures are disclosed for recovering ECGF protein essentially free of other proteins of human origin. The product is useful for, among other purposes, diagnostic applications and as potential in the treatment of damaged blood vessels or other endothelial cell-lined structures.
    Type: Grant
    Filed: March 28, 2000
    Date of Patent: September 17, 2002
    Assignee: Aventis Pharmaceuticals Products Inc.
    Inventors: Michael C. Jaye, Wilson Burgess, Thomas Maciag, William N. Drohan